5-Aminosalicylic acid-d3disodium is a deuterium-labeled variant of 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) functions as a specific PPARγ agonist, and it also inhibits p21-activated kinase 1 (PAK1) and NF-κB. Additionally, it acts to suppress the activity of osteopontin (OPN).

5-Aminosalicylic acid (5-ASA) demonstrates an antineoplastic effect in a xenograft tumor model. In vivo evaluation was conducted using SCID mice implanted with HT-29 colon cancer cells, treated daily with 50 mM 5-ASA for 21 days. This treatment resulted in an 80-86% reduction in tumor weight and volume compared to control mice or those treated solely with GW9662. The antineoplastic effect of 5-ASA was perceivable after just 10 days and was similar when using a 5 mM dose. However, when GW9662 was administered intraperitoneally alongside 5-ASA for 21 days, the antitumorigenic impact was completely nullified, indicating the effect's partial dependence on PPARγ.